Syntara

Chicago, United States

Syntara develops clinical-stage medicines targeting blood cancers, fibrosis, and inflammation using amine oxidase chemistry.

$2.7M raised

Nov 2025

Seed

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Syntara raised?

Syntara has raised $2.7M in total funding. The most recent round was Seed. The last funding was announced in November 2025.

Who are Syntara's investors?

Syntara's investors include Cinder Grove Capital.

Where is Syntara headquartered?

Syntara is headquartered in Chicago, United States.

What does Syntara do?

Syntara develops clinical-stage medicines targeting blood cancers, fibrosis, and inflammation using amine oxidase chemistry.

What stage is Syntara at?

Syntara is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated November 3, 2025.

MLA

"Syntara — Funding & Investors." VCBacked, November 3, 2025, https://www.vcbacked.co/company/syntara. Accessed July 2, 2026.

APA

VCBacked. (2025). Syntara — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/syntara

Wikipedia (cite web)

{{cite web |title=Syntara — Funding & Investors |url=https://www.vcbacked.co/company/syntara |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated November 3, 2025.